Packaging the Alkaloids of Cinchona Bark in Combination with Etoposide in Polymeric Micelles Nanoparticles

Authors: Diky Mudhakir, Satrialdi, Sukmadjaja Asyarie, Yeyet C. Sumirtapura

Abstract:

Today, cancer remains one of the major diseases that lead to death. The main obstacle in chemotherapy as a main cancer treatment is the toxicity to normal cells due to Multidrug Resistance (MDR) after the use of anticancer drugs. Proposed solution to overcome this problem is the use of MDR efflux inhibitor of cinchona alkaloids which is delivered together with anticancer drugs encapsulated in the form of polymeric nanoparticles. The particles were prepared by the hydration method. The characterization of nanoparticles was particle size, zeta potential, entrapment efficiency and in vitro drug release. Combination nanoparticle size ranged 29-45 nm with a neutral surface charge. Entrapment efficiency was above 87% for the use quinine, quinidine or cinchonidine in combination with etoposide. The release test results exhibited that the cinchona alkaloids release released faster than that of etoposide. Collectively, cinchona alkaloids can be packaged along with etoposide in nanomicelles for better cancer therapy.

Keywords: Cinchona alkaloids, etoposide, MDR efflux inhitor, polymeric nanomicelles.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1327853

References:

[1] World Health Organization Media Centre, http://www.who.int/ mediacentre/factsheets/fs297/en/
[2] M.R. Gwinn and V. Vallyathan, "Nanoparticles: Health effects-pros and cons", Env. Health Perspect., vol. 114, no. 12, 2006, p. 1818-1825.
[3] K.T. Oh, H.J. Baik, A.H. Lee, Y.T. Oh, Y.S. Youn, and E.S. Lee, "The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system", Int. J. Mol. Sci., vol. 10, no. 9, 2009, pp. 3776-3792.
[4] F.S. Liu, "Mechanisms of chemotherapeutic drug resistance in cancer therapy-A quick review", Taiwan J. Obstet. Gynecol., vol. 48, no. 3, 2009, pp. 239-242.
[5] W. Jager, "Classical resistance mechanisms", Int. J. of Clinical Pharm. and Therapeutics, vol. 47, no. 1, 2009, pp. 46-48.
[6] M.M. Gottesman, T. Fojo, S.E. Bates,"Multidrug resistance in cancer: Role of ATP-dependent transporters, Macmillan Magazines, vol 2, 2001, pp. 48-58
[7] J.M. Lara S, L.E. van Vlerken, S. Yadaf and MM. Amiin, "Multifunctional nanocarriers to overcome tumor drug resistance", Cancer Treat. Rev., vol. 34, no. 7, 2008, pp. 592-602.
[8] W. Jun, Y. Lu, A. Lee, X. Pan, X. Yang , X. Zhao, and R.J. Lee, "Reversal of multidrug resistance by transferrin-conjugated liposomes Co-en capsulating doxorubicin and verapmil", J. Pharm. Pharmaceut. Sci, vol 10, no. 3, 2007, pp. 350-357.
[9] H.L. Wong, R.. Bedayan, A.M. Rauth, and X.Y. Wu, "Simultaneous delivery of doxorubicin and GG918 by new polymer lipid hybrid nanoparticle for enhanced treatment of multidrug resistant breast cancer", J. Control. Rel., vol. 116, no. 3, 2006, pp. 275-284.
[10] P. Genne, D.B.M., Therese, Y.M. Roland, G. Gutierrez, O. Duchamp, J.M. Petit, F. Martin, B. Chauffert, "Cinchonine, a potent efflux inhitor to circumvent anthracycline resistance in vivo", AACR Journals, vol. 52, no. 10, 1992, pp. 2797-2801.
[11] S. Fusco, A. Borzacchiello, P.A. Netti, "Perspective on PEO-PPO-PEO triblock copolymers and their biomedical applications", J. Bioact Compat Pol., vol. 21, 2006, pp. 149-164.
[12] A. Kabanov E.V. Batrakove, VY. Alakhov, "Pluronic block copolymers for overcoming drug resistance in cancer", Adv. Drug Deliv. Rev., vol. 54, no. 5, 2002, pp. 759-779.
[13] N. Rapoport, G. Zhonggao, H.D. Fain, "Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers", Mol. Pharm., vol. 1, no. 4, 2004, pp. 317-330.
[14] E. Solary, L. Manone, D. Moreau, D. Caillot, R.O. Cassanov, H. Guy, M. Grandjean, J.E. Wolf, F. Andre, P. Fenaux, P. Canal, B. Auffert, A. Wotawa, M. Bayssas, P. Genne, "Phase I study of cinchonine, a multidrug resistence reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferatives syndromes", Leukemia, vol. 14 p. 2085-2094.